AUTHOR=Wu Zeng-Hong , Li Cheng , Zhang You-Jing , Lin Rong 

TITLE=Bioinformatics Study Revealed Significance of Exosome Transcriptome in Hepatocellular Carcinoma Diagnosis

JOURNAL=Frontiers in Cell and Developmental Biology

VOLUME=Volume 10 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.813701

DOI=10.3389/fcell.2022.813701

ISSN=2296-634X

ABSTRACT=Background: Hepatocellular carcinoma (HCC) is counted as the fifty most common cancer globally having a high mortality rate with the second most common cause of cancer-related deaths. However, little attention has been paid to the involvement of exosomes and ceRNA in HCC.
Method: The study aimed to explore exosome data from exoRBase database and a free online database to estimate possible binding miRNA from mRNA, lncRNA, and circRNA and discover useful exosome biomarkers for HCC therapy.
Results: The results indicated that a total of 159 mRNAs, 60 lncRNAs, and 13 circRNAs were differentially expressed, with HIST2H3C exhibiting the highest log2FC change and CTD-2031P19 exhibiting the most relevant lncRNA and CTD-2031P19 exhibiting the most relevant lncRNA. The MARCH8, SH3PXD2A, has-circ-0014088, hsa-miR-186-5p, and hsa-miR-613 were identified as hub biomarkers used by Cytoscape. According to KEGG pathway analysis results, the differentially expressed proteins were primarily enriched in the MAPK signaling network, central carbon metabolism in cancer, the glucagon signaling pathway, glutamatergic synapse, and spliceosome.  Furthermore, immunohistochemical images from the Human Protein Atlas (HPA) online tool was employed to directly evaluate the protein expression of SMARCA5, CDC42, and UBC between normal and cancer tissues, and the results showed that these three genes expression were significantly higher in tumor tissues. 
Conclusion: This study discovered atypical signature exosomes for HCC prognostic prediction based on an online database. The signals could mimic exosome microenvironmental disorders providing potential biomarkers for exosome treatment.